Régime posologique pour un agoniste du récepteur s1p

Dosage regimen for a s1p receptor agonist

Dosierschema für einen s1p-rezeptor-agonisten

Abstract

S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (5)

    Publication numberPublication dateAssigneeTitle
    EP-0627406-A1December 07, 1994Yoshitomi Pharmaceutical Industries, Ltd.2-amino-1, 3- propandiolverbindung und immunosuppressiuum
    WO-0218395-A1March 07, 2002Merck & Co., Inc.Phosphate derivatives as immunoregulatory agents
    WO-03097028-A1November 27, 2003Novartis Ag, Novartis Pharma GmbhUse of edg receptor binding agents in cancer
    WO-2006058316-A1June 01, 2006Novartis Ag, Novartis Pharma GmbhPosologie d'un agoniste du recepteur s1p
    WO-2009048993-A2April 16, 2009Novartis AgCompositions comprising sphingosine 1 phosphate (s1p) receptor modulators

NO-Patent Citations (7)

    Title
    BUDDE K ET AL: "First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 13, no. 4, 1 January 2002 (2002-01-01), pages 1073 - 1083, XP003016978, ISSN: 1046-6673
    DS. 1M ET AL., MOL. PHARMACOL., vol. 57, 2000, pages 753
    KAPPOS L; ANTEL J; COMI G; MONTALBAN X; O'CONNOR P; POLMAN CH; HAAS T; KORN AA; KARLSSON G; RADUE EW: "Oral fingolimod (FTY720) for relapsing multiple sclerosis", FTY720 D2201 STUDY GROUP. N ENGL J MED., vol. 355, no. 11, 14 September 2006 (2006-09-14), pages 1124 - 40
    KOYRAKH LEV ET AL: "The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I.", March 2005, AMERICAN JOURNAL OF TRANSPLANTATION : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF TRANSPLANT SURGEONS MAR 2005, VOL. 5, NR. 3, PAGE(S) 529 - 536, ISSN: 1600-6135, XP002562406
    MEHLING M; BRINKMANN V; ANTEL J; BAR-OR A; GOEBELS N; VEDRINE C; KRISTOFIC C; KUHLE J; LINDBERG RL; KAPPOS L: "FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis", NEUROLOGY, vol. 71, no. 16, 14 October 2008 (2008-10-14), pages 1261 - 7, XP009165260, DOI: doi:10.1212/01.wnl.0000327609.57688.ea
    ROBERT SCHMOUDER; DENISE SERRA; YIBIN WANG; JOHN M. KOVARIK; JOHN DIMARCO; THOMAS L. HUNT; MARIE-CLAUDE BASTIEN: "FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects", J. CLIN. PHARMACOL., vol. 46, 2006, pages 895, XP008107801, DOI: doi:10.1177/0091270006289853
    SCHMOULDER R., ET AL.: "Multiple Sclerosis", vol. 14, part Abst P507 17 September 2008, SAGE, London, article ORAL FINGOLIMOD (FTY720), 0.5 OR 1.25 MG, FOR 14 DAYS HAS NO EFFECT ON CARDIAC FUNCTION: "World Congresson Treatment and Research on Multiple Sclerosis", pages: S177, XP009127649

Cited By (0)

    Publication numberPublication dateAssigneeTitle